Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 1.96% to $472.57 on Wednesday, underperforming competitors like AbbVie and Krystal Biotech during a broader market decline. The stock closed 11.45% below its 52-week high. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) shed 1.96% to $472.57 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.14% to 7,498.96 and Dow Jones Industrial Average falling 0.01% to 52,218.58.
Vertex Pharmaceuticals Inc. closed 11.45% below its 52-week high of $533.67, which the company reached on July 7th.
The stock underperformed when compared to some of its competitors Wednesday, as AbbVie Inc. (ABBV) fell 1.09% to $253.30, Krystal Biotech Inc. (KRYS) fell 0.67% to $336.80, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.00% to $5.93.
Trading volume (1.3 M) remained 308,849 below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 22, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-22-26 1636ET